{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:01:26Z","timestamp":1775304086203,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,5,26]],"date-time":"2012-05-26T00:00:00Z","timestamp":1337990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/2.0"},{"start":{"date-parts":[[2012,5,26]],"date-time":"2012-05-26T00:00:00Z","timestamp":1337990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Approximately 25\u00a0% of clinically important drugs and numerous environmental carcinogens are metabolised by CYP2D6. Variation in the CYP2D6 gene and concomitant use of tamoxifen (TAM) with certain antidepressants may increase recurrence risk in breast cancer patients due to reduced enzyme activity. In this study we determined the appropriateness of adding CYP2D6 genotyping to the breast cancer genetic testing options already available in South Africa, which include BRCA mutation screening and transcriptional profiling to assess estrogen receptor (ER) status. A total of 114 South African breast cancer patients, including 52 Caucasian and 62 Coloured (Mixed ancestry), and 63 Caucasian control individuals were genotyped for the most common inactivating allele (CYP2D6*4, rs3892097) previously identified in the CYP2D6 gene. In the initial validation data set consisting of 25 Caucasian and 62 Coloured patients, the CYP2D6*4 allele frequency was significantly higher in Caucasian compared to Coloured patients (24\u00a0% vs. 3\u00a0%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), similar to previous findings in the general South African population. Extended CYP2D6 genotyping was subsequently performed in an implementation data set of 27 Caucasian breast cancer patients, to determine the prevalence of depression and use of antidepressants in a clinical setting. A medical history of depression and\/or use of antidepressants was reported in 37\u00a0% (10\/27) of these breast cancer patients genotyped for CYP2D6*4. This translational research study has led to increased awareness among clinicians of the potential benefits of CYP2D6 genotyping to facilitate prevention of cumulative risk in a high-risk genetic subgroup of breast cancer patients considered for concomitant treatment of TAM and antidepressants that may reduce enzyme function.<\/jats:p>","DOI":"10.1007\/s11011-012-9312-z","type":"journal-article","created":{"date-parts":[[2012,5,25]],"date-time":"2012-05-25T10:13:17Z","timestamp":1337940797000},"page":"319-326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["CYP2D6 genotyping and use of antidepressants in breast cancer patients: test development for clinical application"],"prefix":"10.1007","volume":"27","author":[{"given":"Nicole","family":"van der Merwe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christianne S. H.","family":"Bouwens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rika","family":"Pienaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lize","family":"van der Merwe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yandiswa Y.","family":"Yako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter H.","family":"Geiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maritha J.","family":"Kotze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,26]]},"reference":[{"key":"9312_CR1","unstructured":"Agenbag GM (2005) Molecular genetic analysis of familial breast cancer in South Africa. Dissertation, Stellenbosch University. http:\/\/hdl.handle.net\/10019\/953"},{"key":"9312_CR2","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.clinbiochem.2009.04.009","volume":"42","author":"B Arneth","year":"2009","unstructured":"Arneth B, Shams M, Hiemke C, Hartter S (2009) Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or\/and duplication of the CYP2D6 gene. Clin Biochem 42:1282\u20131290","journal-title":"Clin Biochem"},{"key":"9312_CR3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1634\/theoncologist.11-2-126","volume":"11","author":"S Bernard","year":"2006","unstructured":"Bernard S, Neville KA, Nguyen AT, Flockhart DA (2006) Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 11:126\u2013135","journal-title":"Oncologist"},{"key":"9312_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.clpt.2006.03.013","volume":"80","author":"S Borges","year":"2006","unstructured":"Borges S, Desta Z, Li L et al (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61\u201374","journal-title":"Clin Pharmacol Ther"},{"key":"9312_CR5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/0091270009359182","volume":"50","author":"S Borges","year":"2010","unstructured":"Borges S, Desta Z, Jin Y et al (2010) Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 50:450\u2013458","journal-title":"J Clin Pharmacol"},{"key":"9312_CR6","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329\u20131333","journal-title":"J Clin Oncol"},{"key":"9312_CR7","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/sj.bjc.6601667","volume":"90","author":"S Cleator","year":"2004","unstructured":"Cleator S, Ashworth A (2004) Molecular profiling of breast cancer: clinical implications. Br J Cancer 90:1120\u20131124","journal-title":"Br J Cancer"},{"key":"9312_CR8","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1097\/FPC.0b013e328012d0a9","volume":"17","author":"T Frudakis","year":"2007","unstructured":"Frudakis T, Thomas M, Ginjupalli S et al (2007) CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogenet Genomics 17:695\u2013707","journal-title":"Pharmacogenet Genomics"},{"key":"9312_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","volume":"83","author":"A Gaedigk","year":"2008","unstructured":"Gaedigk A, Coetsee C (2008) The CYP2D6 gene locus in South African coloureds: unique allele distributions, novel alleles and gene arrangements. Eur J Clin Pharmacol 64:465\u2013475","journal-title":"Clin Pharmacol Ther"},{"key":"9312_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10549-006-9428-0","volume":"101","author":"MP Goetz","year":"2007","unstructured":"Goetz MP, Knox SK, Suman VJ et al (2007) The impact of cytochrome P450 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113\u2013121","journal-title":"Breast Cancer Res Treat"},{"key":"9312_CR11","doi-asserted-by":"crossref","unstructured":"Hertz DL, McLeod HL, Irvin WJ Jr (2012) Tamoxifen and CYP2D6: A Contradiction of Data. Oncologist. Apr 24. [Epub ahead of print]","DOI":"10.1634\/theoncologist.2011-0418"},{"key":"9312_CR12","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/jnci\/djp366","volume":"101","author":"D Holzman","year":"2009","unstructured":"Holzman D (2009) Tamoxifen, antidepressants, and CYP2D6: the conundrum continues. J Natl Cancer Inst 101:1370\u20131371","journal-title":"J Natl Cancer Inst"},{"key":"9312_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/jnci\/dji005","volume":"97","author":"Y Jin","year":"2005","unstructured":"Jin Y, Desta Z, Stearns V et al (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30\u201339","journal-title":"J Natl Cancer Inst"},{"key":"9312_CR14","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/GIM.0b013e31815699d0","volume":"9","author":"MJ Khoury","year":"2007","unstructured":"Khoury MJ, Gwinn M, Yoon PW et al (2007) The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 9:665\u2013674","journal-title":"Genet Med"},{"key":"9312_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4048\/jbc.2010.13.4.325","volume":"13","author":"S Kim","year":"2010","unstructured":"Kim S, Lee M, Lee K et al (2010) Use of antidepressants in patients with breast cancer taking tamoxifen. J Breast Cancer 13:325\u2013336","journal-title":"J Breast Cancer"},{"key":"9312_CR16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"MC King","year":"2003","unstructured":"King MC, Marks JH, Mandell JB, the New York Breast Cancer Study Group (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643\u2013646","journal-title":"Science"},{"key":"9312_CR17","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1200\/JCO.2009.25.7246","volume":"28","author":"K Kiyotani","year":"2010","unstructured":"Kiyotani K, Mushiroda T, Imamura CK et al (2010) Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 28:1287\u20131293","journal-title":"J Clin Oncol"},{"key":"9312_CR18","doi-asserted-by":"publisher","unstructured":"Kotze MJ, van Rensburg SJ (2012) Pathology supported genetic testing and treatment of cardiovascular disease in middle age for prevention of Alzheimer\u2019s disease. Metab Brain Dis. doi:10.1007\/s11011-012-9296-8","DOI":"10.1007\/s11011-012-9296-8"},{"key":"9312_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2165\/00066982-200307030-00005","volume":"7","author":"MJ Kotze","year":"2003","unstructured":"Kotze MJ, Kriegsh\u00e4user G, Thiart R et al (2003) Simultaneous detection of multiple familial hypercholesterolaemia mutations facilitates an improved diagnostic service in South African patients at high risk of cardiovascular disease. Mol Diagn 7:169\u2013174","journal-title":"Mol Diagn"},{"key":"9312_CR20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/20786204.2005.10873286","volume":"47","author":"MJ Kotze","year":"2005","unstructured":"Kotze MJ, Malan J, Pienaar R, Apffelstaedt J (2005) The role of molecular genetic testing in modern breast health management. S Afr Fam Pract 47:38\u201340","journal-title":"S Afr Fam Pract"},{"key":"9312_CR21","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/sj.bjc.6604533","volume":"99","author":"TL Lash","year":"2008","unstructured":"Lash TL, Pedersen L, Cronin-Fenton D (2008) Tamoxifen\u2019s protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer 99:616\u2013621","journal-title":"Br J Cancer"},{"key":"9312_CR22","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1200\/JCO.2009.23.1597","volume":"27","author":"CI Li","year":"2009","unstructured":"Li CI, Daling JR, Porter PL, Tang MT, Malone KE (2009) Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. J Clin Oncol 27:5312\u20135318","journal-title":"J Clin Oncol"},{"key":"9312_CR23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W","volume":"83","author":"N Lomen","year":"1998","unstructured":"Lomen N, Johannsson O, Bendahl PO et al (1998) Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 83:310\u2013319","journal-title":"Cancer"},{"key":"9312_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/gm280","volume":"3","author":"W Lorizio","year":"2011","unstructured":"Lorizio W, Rugo H, Beattie MS et al (2011) Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment. Genome Med 3:64\u201375","journal-title":"Genome Med"},{"key":"9312_CR25","doi-asserted-by":"crossref","unstructured":"Mann A, Miksys SL, Gaedigk A, et al (2011) The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson\u2019s disease patients. Neurobiol Aging Sep 27. [Epub ahead of print]","DOI":"10.1016\/j.neurobiolaging.2011.08.014"},{"key":"9312_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-3-211-45295-0_25","volume":"70","author":"GD Mellick","year":"2006","unstructured":"Mellick GD (2006) CYP450, genetics and Parkinson\u2019s disease: gene x environment interactions hold the key. J Neural Transm Suppl 70:159\u2013165","journal-title":"J Neural Transm Suppl"},{"key":"9312_CR27","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1001\/jama.295.17.2057","volume":"295","author":"HD Nelson","year":"2006","unstructured":"Nelson HD, Vesco KK, Haney E et al (2006) Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 295:2057\u20132071","journal-title":"JAMA"},{"key":"9312_CR28","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-07-5235","volume":"14","author":"WG Newman","year":"2008","unstructured":"Newman WG, Hadfield KD, Latif A, et al (2008) Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res 14:5913\u20135918","journal-title":"Clin Cancer Res"},{"key":"9312_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/00004714-200702000-00005","volume":"27","author":"SH Preskorn","year":"2007","unstructured":"Preskorn SH, Greenblatt DJ, Flockhart D et al (2007) Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol 27:28\u201334","journal-title":"J Clin Psychopharmacol"},{"key":"9312_CR30","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/jnci\/djn100","volume":"100","author":"RS Punglia","year":"2008","unstructured":"Punglia RS, Burstein HJ, Winer EP, Weeks JC (2008) Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst 100:642\u2013648","journal-title":"J Natl Cancer Inst"},{"key":"9312_CR31","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/jnci\/djs126","volume":"104","author":"JM Rae","year":"2012","unstructured":"Rae JM, Drury S, Hayes DF et al (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104:452\u2013460","journal-title":"J Natl Cancer Inst"},{"key":"9312_CR32","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/ijc.20186","volume":"110","author":"MD Reeves","year":"2004","unstructured":"Reeves MD, Yawitch TM, Van der Merwe NC et al (2004) BRCA1 mutations in South African breast and\/or ovarian cancer families: evidence of a novel founder mutation in Afrikaner families. Int J Cancer 110:677\u2013682","journal-title":"Int J Cancer"},{"key":"9312_CR33","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/jnci\/djs125","volume":"104","author":"MM Regan","year":"2012","unstructured":"Regan MM, Leyland-Jones B, Bouzyk M et al (2012) CYP2D6 genotype and Tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1\u201398 trial. J Natl Cancer Inst 104:441\u2013451","journal-title":"J Natl Cancer Inst"},{"key":"9312_CR34","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1093\/annonc\/mdr025","volume":"22","author":"V Rosato","year":"2011","unstructured":"Rosato V, Bosetti C, Talamini R et al (2011) Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann Oncol 22:2687\u20132692","journal-title":"Ann Oncol"},{"key":"9312_CR35","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1001\/jama.2009.1420","volume":"302","author":"W Schroth","year":"2009","unstructured":"Schroth W, Goetz MP, Hamann U et al (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429\u20131436","journal-title":"JAMA"},{"key":"9312_CR36","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10549-010-0817-z","volume":"125","author":"MD Sluiter","year":"2011","unstructured":"Sluiter MD, van Rensburg EJ (2011) Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation. Breast Cancer Res Treat 125:325\u2013349","journal-title":"Breast Cancer Res Treat"},{"key":"9312_CR37","first-page":"347","volume":"16","author":"NC Van der Merwe","year":"2009","unstructured":"Van der Merwe NC, van Rensburg EJ (2009) Hereditary breast\/ovarian cancer and BRCA mutations: a South African perspective. Curr Oncol 16:347","journal-title":"Curr Oncol"},{"key":"9312_CR38","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1399-0004.2010.01617.x","volume":"81","author":"NC Van der Merwe","year":"2012","unstructured":"Van der Merwe NC, Hamel N, Schneider S-R et al (2012) A founder BRCA2 mutation in non-Afrikaner breast cancer patients of the Western Cape of South Africa. Clin Genet 81:179\u2013184","journal-title":"Clin Genet"},{"key":"9312_CR39","first-page":"125S","volume":"19","author":"DA Vorobiof","year":"2001","unstructured":"Vorobiof DA, Sitas F, Vorobiof G (2001) Breast cancer incidence in South Africa. J Clin Oncol 19:125S\u2013127S","journal-title":"J Clin Oncol"},{"key":"9312_CR40","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1469-1809.2010.00585.x","volume":"74","author":"GE Wright","year":"2010","unstructured":"Wright GE, Niehaus DJ, Dr\u00f6gem\u00f6ller BI et al (2010) Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet 74:340\u2013350","journal-title":"Ann Hum Genet"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-012-9312-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-012-9312-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s11011-012-9312-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-012-9312-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T18:58:17Z","timestamp":1630522697000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-012-9312-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,26]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["9312"],"URL":"https:\/\/doi.org\/10.1007\/s11011-012-9312-z","relation":{},"ISSN":["0885-7490","1573-7365"],"issn-type":[{"value":"0885-7490","type":"print"},{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,26]]},"assertion":[{"value":"4 January 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}